All In Biotech

Drug Trial Radar · NCT05941806

Prophylactic Use of Tamsulosin in the Prevention of Post-operative Urinary Retention in Men After Rectum Resection

Prophylactic Use of Tamsulosin in the Prevention of Post-operative Urinary Retention in Men After Rectum Resection: a Double-blind Placebo-controlled Clinical Trial

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Nov 10, 2023

Primary completion

Jul 30, 2027

Study completion Jul 30, 2028

Sponsor

Lead sponsor
CHU de Quebec-Universite LavalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fédération des médecins résidents du Québec
First posted
Jul 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will be a phase III double-blind randomized clinical trial. Participants will be recruited from the Department of General Surgery of the CHU de Québec - Saint-François-d'Assise and Hôtel-Dieu de Québec. The primary outcomes are the incidence of postoperative urinary retention in men undergoing rectal resection and the efficacy of prophylactic tamsulosin to prevent this type of complication.The secondary outcomes are the length of stay between experimental and placebo groups, the number of urinary catheterizations, the number of urine catheter reinsertions and total duration of urinary catheter being in-situ.

Conditions

  • Urinary Retention
  • Colorectal Surgery
  • Rectal Resection
  • Post-operative Urinary Retention
  • Tamsulosin

Interventions

  • pr Sandoz TamsulosinDrug

    Sandoz Tamsulosin, the study drug, is an alpha1-adrenergic blocking agent approved by Health Canada for men with bladder outlet obstruction symptoms associated with benign prostatic hyperplasia.

  • GlucoseDrug

    Patients assigned to the placebo group will receive glucose capsules according to the same protocol. The glucose capsules will be manufactured by the pharmacy of the CHU de Quebec

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Postoperative urinary retentionTime frame: During the length of hospital stay: up to two weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hôpital Saint-François d'Assise

    Québec, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.